| Literature DB >> 31307487 |
Ellen Nordal1,2, Veronika Rypdal3,4, Ellen Dalen Arnstad5,6, Kristiina Aalto7, Lillemor Berntson8, Maria Ekelund8,9, Anders Fasth10, Mia Glerup11, Troels Herlin11, Susan Nielsen12, Suvi Peltoniemi7, Marek Zak12, Nils Thomas Songstad3,4, Marite Rygg5,13.
Abstract
BACKGROUND: The aim of the study was to describe school attendance and participation in physical education in school among children with juvenile idiopathic arthritis (JIA).Entities:
Keywords: Epidemiology; Juvenile idiopathic arthritis; Participation; Physical activity; Physical education; School
Year: 2019 PMID: 31307487 PMCID: PMC6631827 DOI: 10.1186/s12969-019-0341-6
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Clinical characteristics at the eight-year study visit comparing children with juvenile idiopathic arthritis with and without information on physical education (PE) and school attendance
| Characteristics at final study visit ( | Participants with information on PE or school attendance ( | Participants without information on PE or school attendance ( | ||
|---|---|---|---|---|
|
| n (%) or median (IQR) |
| n (%) or median (IQR) | |
| Female, n (%) | 285 | 188 (66.0) | 62 | 39 (62.9) |
| Age at disease onset, years | 285 | 5.3 (2.3–9.4) | 62 | 8.3 (3.8–11.2) |
| Cumulative joint count | 285 | 6 (2–12) | 62 | 4 (2–10) |
| Active joints | 285 | 0.0 (0.0–0.0) | 62 | 0.0 (0.0–0.0) |
| Physician GA, VAS | 192 | 0.0 (0.0–0.9) | 4 | 0.3 (0.1–1.8) |
| Patient/parent GA, VAS | 216 | 0.0 (0.0–1.2) | 3 | 0.3 (0.0–0.5) |
| Pain VAS | 220 | 0.0 (0.0–1.3) | 3 | 0.0 (0.0–0.5) |
| CHAQ score | 285 | 0.0 (0.0–0.1) | 8 | 0.0 (0.0–0.1) |
| CHQ-PF50, PhS score | 160 | 52.5 (45.5–56.9) | 4 | 46.8 (36.2–53.9) |
| CHQ-PF50, PsS score | 160 | 54.8 (48.0–59.6) | 4 | 40.9 (32.4–46.8) |
| DMARDs, n (%) | 285 | 102 (35.8) | 62 | 8 (12.9) |
| Oligoarticular persistent, n (%) | 285 | 84 (29.5) | 62 | 25 (40.3) |
| Oligoarticular extended, n (%) | 285 | 49 (17.2) | 62 | 8 (12.9) |
| Polyarticular RF negative, n (%) | 285 | 58 (20.3) | 62 | 7 (11.3) |
| Polyarticular RF positive, n (%) | 285 | 2 (0.7) | 62 | 1 (1.6) |
| Systemic arthritis, n (%) | 285 | 8 (2.8) | 62 | 1 (1.6) |
| Psoriatic arthritis, n (%) | 285 | 13 (4.6) | 62 | 0 (0) |
| Enthesitis-related arthritis, n (%) | 285 | 29 (10.2) | 62 | 12 (19.3) |
| Undifferentiated arthritis, n (%) | 285 | 42 (14.7) | 62 | 8 (12.9) |
| ESR mm/hour | 193 | 7.0 (4.0–11.0) | 14 | 8.5 (6.0–14.0) |
| CRP mg/liter | 201 | 0.0 (0.0–5.0) | 12 | 2.5 (0.0–7.5) |
| RF positive, n (%) | 150 | 5 (3.3) | 29 | 2 (6.9) |
| HLA-B27 positive, n (%) | 274 | 62 (22.6) | 52 | 11 (21.2) |
| ANA positive, n (%) | 284 | 66 (23.2) | 60 | 13 (21.7) |
Values are the median (interquartile range, IQR), unless indicated otherwise. PE Physical education and school attendance assessed at the eight-year study visit, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, ANA Antinuclear antibody, assessed twice with at least 3 months interval, RF Rheumatoid factor, assessed twice with at least 3 months interval, HLA-B27 Human leucocyte antigen
Fig. 1Number of days of school absence because of JIA during the last 2 months among participants in the Nordic JIA study. a assessed at the baseline study visit 7 months after disease onset (n = 95). b assessed at the eight-year study visit (n = 274)
Characteristics of 274 children in the Nordic JIA cohort according to school absence at the eight-year study visita
| Characteristics at the eight-year visit | n | Absence ≤1 day ( | Absence > 1 day ( | OR (95% CI) | |
|---|---|---|---|---|---|
| Female, n (%) | 274 | 148 (64.9) | 32 (69.6) | 1.2 (0.6–2.4) | 0.545 |
| Age disease onset, years | 274 | 5.2 (2.3–9.2) | 4.6 (2.3–8.7) | 1.0 (0.9–1.1) | 0.440 |
| BMI | 234 | 19.5 (17.3–21.6) | 19.8 (17.2–24.8) | 1.1 (1.0–1.2) | 0.117 |
| Cumulative joint count | 274 | 5 (2–10) | 11 (5–14) | 1.0 (1.0–1.0) | 0.007 |
| Active joints | 274 | 0 (0–0) | 0 (0–1) | 1.5 (1.2–1.9) | 0.002 |
| Physician GA | 190 | 0.0 (0.0–0.5) | 1.0 (0.2–2.1) | 7.1 (2.7–18.5) | < 0.001 |
| Patient/parent GA | 213 | 0.0 (0.0–0.6) | 1.2 (0.0–2.5) | 3.5 (1.8–6.8) | < 0.001 |
| Pain VAS | 217 | 0.0 (0.0–0.8) | 1.4 (1.0–3.5) | 3.5 (1.9–6.5) | < 0.001 |
| CHAQ | 274 | 0.0 (0.0–0.0) | 0.3 (0.0–0.6) | 10.1 (4.4–23.1) | < 0.001 |
| CHQ-PF50, PhS | 159 | 53.4 (47.9–57.3) | 41.8 (32.1–50.4) | 0.9 (0.8–0.9) | < 0.001 |
| CHQ-PF50, PsS | 159 | 54.9 (47.5–60.1) | 54.3 (49.7–58.4) | 1.0 (0.9–1.1) | 0.792 |
| DMARDs, n (%) | 274 | 72 (31.6) | 27 (58.7) | 1.8 (1.3–2.7) | 0.002 |
| JADAS10 | 174 | 0.4 (0.0–2.2) | 3.5 (0.6–6.1) | 1.3 (1.2–1.5) | < 0.001 |
| Not in remission, n (%) | 267 | 126 (56.8) | 42 (93.3) | 10.7 (3.2–35.5) | < 0.001 |
| ESR mm/hour | 193 | 7.0 (4.0–11.0) | 8.0 (4.0–13.0) | 1.0 (1.0–1.1) | 0.110 |
| CRP mg/liter | 201 | 0.0 (0.0–5.0) | 0.0 (0.0–5.0) | 1.0 (1.0–1.1) | 0.168 |
| RF positive | 147 | 3 (2.6) | 2 (6.3) | 2.5 (0.4–15.6) | 0.330 |
| HLA-B27 positive | 264 | 45 (20.6) | 15 (32.6) | 1.9 (0.9–3.7) | 0.081 |
| ANA positive | 273 | 57 (25.1) | 7 (15.2) | 0.5 (0.2–1.3) | 0.154 |
aPatient-/ proxy-reported school absence because of JIA during the preceding 2 months of the eight-year study visit with univariate logistic regression. Values are the median (interquartile range, IQR), unless indicated otherwise, OR Odds ratio, CI Confidence interval, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, Not in remission Not in remission off medication according to the Wallace preliminary criteria [21], ESR Erythrocyte sedimentation rate, CRP C-reactive protein, RF Rheumatoid factor, assessed twice with at least 3 months interval, HLA-B27 Human leucocyte antigen, ANA Antinuclear antibody, assessed twice with at least 3 months interval
Fig. 2Participation in physical education in school within the last 2 months before the baseline study visit reported 7 months after disease onset (n=89), at the 1-year visit (n=84), the 3-year visit (n=113), and the 8-year visit (n=242)
Characteristics of 242 children in the Nordic JIA cohort according to PE participation at the 8 year visita
| Characteristics at the eight-year visit | Total | Full PE | Partly or no PE | OR (95% CI) | |
|---|---|---|---|---|---|
| Females, n (%) | 242 | 119 (61.3) | 39 (81.3) | 2.7 (1.3–6.0) | 0.012 |
| Age at disease onset, years | 242 | 4.4 (2.2–7.3) | 4.6 (2.3–8.7) | 1.0 (0.9–1.1) | 0.398 |
| BMI | 205 | 18.9 (16.8–21.0) | 21.2 (17.8–23.5) | 1.1 (1.0–1.2) | 0.013 |
| Cumulative joint count | 242 | 5 (2–9) | 12 (4–16) | 1.1 (1.0–1.1) | < 0.001 |
| Active joints | 242 | 0 (0–0) | 0 (0–2) | 2.0 (1.4–2.8) | < 0.001 |
| Physician GA, VAS | 188 | 0.0 (0.0–0.5) | 0.9 (0.2–2.0) | 7.1 (2.7–18.8) | < 0.001 |
| Patient/parent GA, VAS | 212 | 0.0 (0.0–0.4) | 1.6 (0.3–3.4) | 6.1 (2.9–12.6) | < 0.001 |
| Pain VAS | 216 | 0.0 (0.0–0.5) | 2.0 (0.8–5.6) | 7.8 (3.8–15.9) | < 0.001 |
| CHAQ score | 242 | 0.0 (0.0–0.0) | 0.3 (0.0–1.0) | 15.0 (5.9–38.6) | < 0.001 |
| CHQ-PF50, PhS score | 156 | 53.9 (48.5–57.3) | 41.5 (31.1–48.2) | 0.9 (0.8–0.9) | < 0.001 |
| CHQ-PF50, PsS score | 156 | 56.0 (49.9–60.1) | 50.3 (44.6–55.8) | 0.9 (0.9–1.0) | 0.010 |
| DMARDs, n (%) | 242 | 64 (33.0) | 24 (50.0) | 1.5 (1.1–2.2) | 0.025 |
| JADAS10 | 147 | 0.1 (0.0–1.9) | 4.7 (1.9–8.0) | 1.5 (1.3–1.7) | < 0.001 |
| Not in remission, n (%) | 236 | 106 (55.8) | 42 (91.3) | 6.5 (2.5–17.2) | < 0.001 |
| ESR mm/hour | 164 | 7.0 (4.0–10.0) | 12.0 (5.0–16.0) | 1.1 (1.0–1.1) | 0.029 |
| CRP mg/liter | 169 | 0.0 (0.0–5.0) | 0.0 (0.0–5.0) | 1.0 (0.9–1.0) | 0.851 |
| RF positive, n (%) | 123 | 1.0 (1.1) | 0 | n.a | n.a |
| HLA-B27 positive, n (%) | 233 | 42 (22.6) | 10 (21.3) | 0.9 (0.4–2.0) | 0.848 |
| ANA positive, n (%) | 241 | 51 (26.4) | 8 (16.7) | 0.6 (0.2–1.3) | 0.164 |
aPatient-/ proxy-reported participation in physical education due to JIA during the preceding 2 months of the eight-year study visit, univariate logistic regression. Values are the median (interquartile range, IQR), unless indicated otherwise, OR Odds ratio, CI Confidence interval, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, Not in remission Not in remission off medication according to the Wallace preliminary criteria [21], ESR Erythrocyte sedimentation rate, CRP C-reactive protein, RF Rheumatoid factor, assessed twice with at least 3 months interval, n.a. Not applicable, HLA-B27 Human leucocyte antigen, ANA Antinuclear antibody, assessed twice with at least 3 months interval
Participation in physical education (PE) in 242 children at the eight-year study visit in the Nordic juvenile idiopathic arthritis (JIA) cohort according to different JIA categories
| JIA categories | Full PE | No or partly PE | OR (95% CI)a | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| Oligoarticular persistent | 73 (93.6) | 5 (6.4) | n.a | n.a |
| Oligoarticular extended | 33 (78.6) | 9 (21.4) | 4.0 (1.2–12.8) | 0.020 |
| Polyarticular RF negative | 39 (78.0) | 11 (22.0) | 4.1 (1.3–12.7) | 0.014 |
| Polyarticular RF positive | 0 | 0 | n.a | n.a |
| Systemic arthritis | 5 (83.3) | 1 (16.7) | 2.9 (0.3–30.0) | 0.367 |
| Psoriatic arthritis | 10 (83.3) | 2 (16.7) | 2.9 (0.5–17.1) | 0.235 |
| Enthesitis-related arthritis | 13 (65.0) | 7 (35.0) | 7.9 (2.2–28.6) | 0.002 |
| Undifferentiated arthritis | 21 (61.8) | 13 (38.2) | 9.0 (2.9–28.3) | < 0.001 |
aUnivariate regression analysis with oligoarticular persistent arthritis as a reference category. OR Odds ratio, CI Confidence interval, RF Rheumatoid factor, n.a Not applicable